EP0650367A1 - Verhinderung interzellulärer wechselwirkungen mit chimären cd43-molekülen - Google Patents

Verhinderung interzellulärer wechselwirkungen mit chimären cd43-molekülen

Info

Publication number: EP0650367A1
Authority: EP; European Patent Office
Prior art keywords: cell; molecule; cell targeting; targeting molecule; binding portion
Prior art date: 1992-06-01
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP93913851A

Other languages

English (en)

French (fr)

Other versions

EP0650367A4 (de

Inventor

Blair Ardman

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Tufts Medical Center Inc

Original Assignee

New England Medical Center Hospitals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-06-01

Filing date

1993-05-13

Publication date

1995-05-03

1993-05-13 Application filed by New England Medical Center Hospitals Inc filed Critical New England Medical Center Hospitals Inc

1995-05-03 Publication of EP0650367A1 publication Critical patent/EP0650367A1/de

1998-04-15 Publication of EP0650367A4 publication Critical patent/EP0650367A4/de

Status Withdrawn legal-status Critical Current

Links

230000008611 intercellular interaction Effects 0.000 title claims abstract description 17
230000000903 blocking effect Effects 0.000 title description 9
102100039564 Leukosialin Human genes 0.000 claims abstract description 187
101000608935 Homo sapiens Leukosialin Proteins 0.000 claims abstract description 183
230000027455 binding Effects 0.000 claims abstract description 77
230000008685 targeting Effects 0.000 claims abstract description 61
230000003993 interaction Effects 0.000 claims abstract description 23
241000124008 Mammalia Species 0.000 claims abstract description 12
210000004027 cell Anatomy 0.000 claims description 218
108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims description 29
102000005962 receptors Human genes 0.000 claims description 27
108020003175 receptors Proteins 0.000 claims description 27
210000002889 endothelial cell Anatomy 0.000 claims description 17
230000001717 pathogenic effect Effects 0.000 claims description 16
206010061218 Inflammation Diseases 0.000 claims description 15
230000004054 inflammatory process Effects 0.000 claims description 15
CMQZRJBJDCVIEY-UHFFFAOYSA-N lacto-N-fucopentaose III Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(CO)OC(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)C1NC(C)=O CMQZRJBJDCVIEY-UHFFFAOYSA-N 0.000 claims description 15
LAQPKDLYOBZWBT-NYLDSJSYSA-N (2s,4s,5r,6r)-5-acetamido-2-{[(2s,3r,4s,5s,6r)-2-{[(2r,3r,4r,5r)-5-acetamido-1,2-dihydroxy-6-oxo-4-{[(2s,3s,4r,5s,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}hexan-3-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-4-hydroxy-6-[(1r,2r)-1,2,3-trihydrox Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@@H](NC(C)=O)C=O)[C@@H]([C@H](O)CO)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 LAQPKDLYOBZWBT-NYLDSJSYSA-N 0.000 claims description 14
244000052769 pathogen Species 0.000 claims description 14
108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 claims description 12
102100023543 Vascular cell adhesion protein 1 Human genes 0.000 claims description 12
150000001413 amino acids Chemical class 0.000 claims description 10
102100023472 P-selectin Human genes 0.000 claims description 9
210000000265 leukocyte Anatomy 0.000 claims description 9
108010024212 E-Selectin Proteins 0.000 claims description 8
102100023471 E-selectin Human genes 0.000 claims description 8
241000709661 Enterovirus Species 0.000 claims description 8
108010035766 P-Selectin Proteins 0.000 claims description 8
241000725303 Human immunodeficiency virus Species 0.000 claims description 5
241000224016 Plasmodium Species 0.000 claims description 5
230000001524 infective effect Effects 0.000 claims description 5
206010061598 Immunodeficiency Diseases 0.000 claims description 4
208000029462 Immunodeficiency disease Diseases 0.000 claims description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
230000007813 immunodeficiency Effects 0.000 claims description 4
208000015181 infectious disease Diseases 0.000 claims description 4
241000223960 Plasmodium falciparum Species 0.000 claims description 2
241000223821 Plasmodium malariae Species 0.000 claims description 2
210000004962 mammalian cell Anatomy 0.000 claims description 2
229940118768 plasmodium malariae Drugs 0.000 claims description 2
125000005630 sialyl group Chemical group 0.000 claims description 2
102100022339 Integrin alpha-L Human genes 0.000 claims 2
108010008212 Integrin alpha4beta1 Proteins 0.000 claims 2
201000010099 disease Diseases 0.000 claims 1
238000000034 method Methods 0.000 abstract description 9
230000002401 inhibitory effect Effects 0.000 abstract description 7
210000001744 T-lymphocyte Anatomy 0.000 description 64
210000004698 lymphocyte Anatomy 0.000 description 43
230000001404 mediated effect Effects 0.000 description 26
230000000694 effects Effects 0.000 description 21
102000005348 Neuraminidase Human genes 0.000 description 15
108010006232 Neuraminidase Proteins 0.000 description 15
PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 14
PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 14
108090000623 proteins and genes Proteins 0.000 description 12
230000001225 therapeutic effect Effects 0.000 description 12
238000002474 experimental method Methods 0.000 description 11
102000004169 proteins and genes Human genes 0.000 description 11
108010084313 CD58 Antigens Proteins 0.000 description 9
230000008614 cellular interaction Effects 0.000 description 8
230000001419 dependent effect Effects 0.000 description 8
102000037865 fusion proteins Human genes 0.000 description 8
108020001507 fusion proteins Proteins 0.000 description 8
125000005629 sialic acid group Chemical group 0.000 description 8
238000003556 assay Methods 0.000 description 7
210000003038 endothelium Anatomy 0.000 description 7
230000006870 function Effects 0.000 description 7
108010002350 Interleukin-2 Proteins 0.000 description 6
102000000588 Interleukin-2 Human genes 0.000 description 6
239000012980 RPMI-1640 medium Substances 0.000 description 6
102100025237 T-cell surface antigen CD2 Human genes 0.000 description 6
210000002865 immune cell Anatomy 0.000 description 6
239000003446 ligand Substances 0.000 description 6
108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 5
108010047620 Phytohemagglutinins Proteins 0.000 description 5
102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 5
230000002939 deleterious effect Effects 0.000 description 5
230000001885 phytohemagglutinin Effects 0.000 description 5
102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 4
108010005832 Leukosialin Proteins 0.000 description 4
230000004913 activation Effects 0.000 description 4
239000000853 adhesive Substances 0.000 description 4
230000001070 adhesive effect Effects 0.000 description 4
238000013459 approach Methods 0.000 description 4
150000001720 carbohydrates Chemical class 0.000 description 4
235000014633 carbohydrates Nutrition 0.000 description 4
230000003511 endothelial effect Effects 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
210000005259 peripheral blood Anatomy 0.000 description 4
239000011886 peripheral blood Substances 0.000 description 4
238000011533 pre-incubation Methods 0.000 description 4
206010003445 Ascites Diseases 0.000 description 3
102000016289 Cell Adhesion Molecules Human genes 0.000 description 3
108010067225 Cell Adhesion Molecules Proteins 0.000 description 3
229920002306 Glycocalyx Polymers 0.000 description 3
210000003719 b-lymphocyte Anatomy 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
210000004517 glycocalyx Anatomy 0.000 description 3
230000028709 inflammatory response Effects 0.000 description 3
230000002452 interceptive effect Effects 0.000 description 3
239000012528 membrane Substances 0.000 description 3
230000037361 pathway Effects 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
239000003053 toxin Substances 0.000 description 3
231100000765 toxin Toxicity 0.000 description 3
BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
101000622137 Homo sapiens P-selectin Proteins 0.000 description 2
241000598436 Human T-cell lymphotropic virus Species 0.000 description 2
206010042971 T-cell lymphoma Diseases 0.000 description 2
208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
230000001464 adherent effect Effects 0.000 description 2
239000000427 antigen Substances 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
230000008901 benefit Effects 0.000 description 2
SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 2
230000017455 cell-cell adhesion Effects 0.000 description 2
238000012412 chemical coupling Methods 0.000 description 2
238000010276 construction Methods 0.000 description 2
210000003989 endothelium vascular Anatomy 0.000 description 2
BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
239000012133 immunoprecipitate Substances 0.000 description 2
230000005732 intercellular adhesion Effects 0.000 description 2
230000008606 intracellular interaction Effects 0.000 description 2
239000002609 medium Substances 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
206010039073 rheumatoid arthritis Diseases 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
230000009450 sialylation Effects 0.000 description 2
230000009870 specific binding Effects 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
UHEPSJJJMTWUCP-DHDYTCSHSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-[(1r)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;sulfuric acid Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N UHEPSJJJMTWUCP-DHDYTCSHSA-N 0.000 description 1
SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
208000011691 Burkitt lymphomas Diseases 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
240000004282 Grewia occidentalis Species 0.000 description 1
241000282412 Homo Species 0.000 description 1
101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
101000995200 Homo sapiens Neurabin-2 Proteins 0.000 description 1
102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
102100038609 Lactoperoxidase Human genes 0.000 description 1
108010023244 Lactoperoxidase Proteins 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
241001529936 Murinae Species 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 1
230000004989 O-glycosylation Effects 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
239000012979 RPMI medium Substances 0.000 description 1
102000003800 Selectins Human genes 0.000 description 1
108090000184 Selectins Proteins 0.000 description 1
241000191940 Staphylococcus Species 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
108091008874 T cell receptors Proteins 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
206010047115 Vasculitis Diseases 0.000 description 1
241000607626 Vibrio cholerae Species 0.000 description 1
-1 acetoxymethyl ester Chemical class 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
230000000181 anti-adherent effect Effects 0.000 description 1
230000003190 augmentative effect Effects 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
238000007675 cardiac surgery Methods 0.000 description 1
230000004956 cell adhesive effect Effects 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
230000015861 cell surface binding Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000009795 derivation Methods 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
230000006806 disease prevention Effects 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000000684 flow cytometry Methods 0.000 description 1
239000012634 fragment Substances 0.000 description 1
230000004927 fusion Effects 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
210000001280 germinal center Anatomy 0.000 description 1
102000050471 human SPN Human genes 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
230000028993 immune response Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000036039 immunity Effects 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
238000001114 immunoprecipitation Methods 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
238000013383 initial experiment Methods 0.000 description 1
108010044426 integrins Proteins 0.000 description 1
102000006495 integrins Human genes 0.000 description 1
210000001503 joint Anatomy 0.000 description 1
229940057428 lactoperoxidase Drugs 0.000 description 1
239000007788 liquid Substances 0.000 description 1
244000144972 livestock Species 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
201000004792 malaria Diseases 0.000 description 1
230000001785 maturational effect Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
239000000203 mixture Substances 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
230000003990 molecular pathway Effects 0.000 description 1
239000003068 molecular probe Substances 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
201000009240 nasopharyngitis Diseases 0.000 description 1
239000013642 negative control Substances 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
239000002674 ointment Substances 0.000 description 1
229920001542 oligosaccharide Polymers 0.000 description 1
150000002482 oligosaccharides Chemical class 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000008844 regulatory mechanism Effects 0.000 description 1
230000001846 repelling effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
238000009738 saturating Methods 0.000 description 1
241000894007 species Species 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000002626 targeted therapy Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000003966 vascular damage Effects 0.000 description 1
210000000264 venule Anatomy 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
206010047470 viral myocarditis Diseases 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/7056—Lectin superfamily, e.g. CD23, CD72
- C07K14/70564—Selectins, e.g. CD62
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70542—CD106
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70546—Integrin superfamily
- C07K14/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

a negatively charged CD43 extracellular domain may be fused to the receptors VCAM-1 and ICAM-l to produce chimeric proteins CD43:VCAM-1 and CD43:ICAM-l; such proteins bind and coat the surface of certain types of leukocytes, blocking interaction with their endothelial counterreceptors and therefore the intracellular interaction between the immune cells and the endothelium which leads to inflammation.
the cotransfected cells were screened by immunofluorescence for CD43 expression, using an anti-CD43 monoclonal antibody, termed anti-Leu 22 (Becton Dickinson, Lincoln Park, NJ) . All CD43-positive HeLa cell clones selected by this method consistently expressed CD43 for the duration of the experiments (>6 mo) .
CD43 A notable feature of CD43 is its extensive substitution with negatively charged, sialic acid residues (Remold et al., J . Biol . Chem . 261:7526, 1986; Carlsson et al., J . Biol . Chem . 261:12779, 1986). It has been proposed that these sialic acid residues confer an anti-adhesion function to CD43 by providing a net negative charge to cell surfaces, resulting in repulsion between CD43-positive cells (Brown et al., Nature (London) 289:456-460, 1981) .
CD43 Two distinctive features of CD43 are the extensive O-glycosylation and sialylation of its extracellular domain (Remod-O'Donnell et al., J. Biol . Chem . 261:7526- 7530, 1986; Carlsson et al., J. Biol . Chem . 261:12779- 12786, 1986; Pallant et al., Proc . Natl . Acad . Sci . USA 86:1328-1332, 1989; Shelly et al., Proc . Natl . Acad . Sci . USA 86:2819-2823, 1989).
the CD43 domain is not only negatively charged but also of sufficient size to physically interfere with the intercellular interaction.
the CD43 domain includes the N-terminal 180 amino acids and, more preferably, includes the N-terminal 220-233 amino acids of the CD43 sequence (as described, e.g., in Shelley et al., Proc . Natl . Acad . Sci . USA 86:2819, 1989; Pallant et al., Proc. Natl . Acad . Sci . USA 86:1328, 1989).
the cell targeting molecule can be chosen from ligands, receptors, counterreceptors, antibodies, carbohydrates, or any molecule which is capable of specific interaction with a surface molecule on the targeted cell.
the cell targeting domain must also be soluble and, in addition, must be of sufficient size and composition to direct specific interaction with its binding partner on the target cell surface.
the cell targeting domain preferably includes between the N-terminal 430 and N-terminal 452 amino acids of the ICAM-l sequence described by Staunton et al. (Cell 52:925, 1988);
VCAM-1 the cell targeting domain preferably includes between the N-terminal 580 and the N- terminal 606 amino acids of the VCAM-1 sequence described by Osborn et al.
CD43:LNF III, CD43:sialyl Lewis x , CD43:ICAM-1, and CD43:VCAM-1 therapeutic proteins are particularly useful for blocking interactions between white blood cells and activated endothelium and are therefore useful for treating or preventing inflammatory disorders, for example, the vasculitis disorders, lupus and rheumatoid arthritis, as well as for suppressing downstream immune responses leading, for example, to organ rejection.
CD43:ICAM-l may also be used to disrupt cell-mediated, organ-specific inflammation secondary to virus infection thus could be useful for treating disorders such as viral myocarditis.

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Toxicology (AREA)
Cell Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

EP93913851A 1992-06-01 1993-05-13 Verhinderung interzellulärer wechselwirkungen mit chimären cd43-molekülen. Withdrawn EP0650367A4 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US89157192A	1992-06-01	1992-06-01
US891571		1992-06-01
PCT/US1993/004517 WO1994000143A1 (en)	1992-06-01	1993-05-13	Blocking intercellular interactions with cd43 chimeric molecules

Publications (2)

Publication Number	Publication Date
EP0650367A1 true EP0650367A1 (de)	1995-05-03
EP0650367A4 EP0650367A4 (de)	1998-04-15

Family

ID=25398441

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP93913851A Withdrawn EP0650367A4 (de)	1992-06-01	1993-05-13	Verhinderung interzellulärer wechselwirkungen mit chimären cd43-molekülen.

Country Status (3)

Country	Link
EP (1)	EP0650367A4 (de)
JP (1)	JPH07507278A (de)
WO (1)	WO1994000143A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5646248A (en)	1993-06-08	1997-07-08	La Jolla Cancer Research Foundation	E-selection binding soluble lamp-1 polypeptide
US5980034A (en) *	1996-03-11	1999-11-09	Videojet Systems International, Inc.	Cross flow nozzle system for an ink jet printer
US7605177B2 (en)	2001-05-24	2009-10-20	Neuren Pharmaceuticals Limited	Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
CA2651866C (en) *	2006-05-11	2014-10-28	Universiteit Gent	Sialoadhesin-related compositions and methods
SG10201808811QA (en)	2014-04-10	2018-11-29	Seattle Childrens Hospital Dba Seattle Childrens Res Inst	Method and compositions for cellular immunotherapy
MX2018001568A (es)	2015-08-07	2019-04-25	Seattle Children´S Hospital Dba Seattle Children´S Res Institute	Celulas t biespecificas de receptor quimerico de antigeno (car) para focalizacion a tumores solidos.
WO2018111763A1 (en)	2016-12-12	2018-06-21	Seattle Children's Hospital (dba Seattle Children's Research Institute)	Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
WO2018140730A1 (en)	2017-01-27	2018-08-02	Signalrx Pharmaceuticals, Inc.	Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK0745852T3 (da) *	1989-03-16	2002-10-14	Blood Res Center	Anvendelse af funktionelle derivater af intercellulær adhæsion-molekylet ICAM-1 i antiviral terapi
WO1992005188A1 (en) *	1990-09-14	1992-04-02	Biogen, Inc.	Production of multimeric glycoproteins through chemical coupling

1993
- 1993-05-13 EP EP93913851A patent/EP0650367A4/de not_active Withdrawn
- 1993-05-13 JP JP5519683A patent/JPH07507278A/ja active Pending
- 1993-05-13 WO PCT/US1993/004517 patent/WO1994000143A1/en not_active Ceased

Also Published As

Publication number	Publication date
EP0650367A4 (de)	1998-04-15
WO1994000143A1 (en)	1994-01-06
JPH07507278A (ja)	1995-08-10

Legal Events

Date	Code	Title	Description
1995-03-17	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
1995-05-03	17P	Request for examination filed	Effective date: 19941229
1995-05-03	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE
1996-01-10	RHK1	Main classification (correction)	Ipc: A61K 38/00
1998-04-15	A4	Supplementary search report drawn up and despatched	Effective date: 19980227
1998-04-15	AK	Designated contracting states	Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE
1998-05-29	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN
1998-07-15	18W	Application withdrawn	Withdrawal date: 19980518

Publication	Publication Date	Title
Ardman et al.	1992	CD43 interferes with T-lymphocyte adhesion.
Schwartz et al.	1990	Identification of surface proteins mediating adherence of CD11/CD18-deficient lymphoblastoid cells to cultured human endothelium.
EP0408859B1 (de)	1995-08-09	Monoklonale Antikörper gegen aktivierte endotheliale Zellen
DK175491B1 (da)	2004-11-08	Anvendelse af ICAM-1 og dets funktionelle derivater til behandling af ikke-specifik inflammation
EP0488061B1 (de)	1998-11-04	Die Mac-1-Bindungsstelle von ICAM-1
US5858981A (en)	1999-01-12	Method of inhibiting phagocytosis
HU214247B (hu)	1998-03-02	Eljárás sejtközi adhéziós molekula ICAM-2 és kötőligandjai előállítására
US6630313B2 (en)	2003-10-07	Phosphatidyl serine receptors and uses thereof
WO1994000143A1 (en)	1994-01-06	Blocking intercellular interactions with cd43 chimeric molecules
AU701919B2 (en)	1999-02-11	Methods of inhibiting phagocytosis
AU723595B2 (en)	2000-08-31	Methods of inhibiting phagocytosis
CA2141600A1 (en)	1994-02-17	Cloning, expression and uses for neurocan as a chondroitin sulfate proteoglycan
WO1994003601A9 (en)	1994-03-31	Cloning, expression and uses for neurocan as a chondroitin sulfate proteoglycan
Mathison et al.	2003	Modulation of neutrophil function by the tripeptide feG
Root	1990	Leukocyte adhesion proteins: their role in neutrophil function
US6066321A (en)	2000-05-23	Method for antagonizing vascular adhesion protein-1 (VAP-1)-mediated binding of endothelial cells to lymphocytes
EP0505749A2 (de)	1992-09-30	Gegen aktivierte Endothelialzellen gerichtete monoklonale Antikörper und deren therapeutische und diagnostische Verwendung
US7399847B1 (en)	2008-07-15	Nucleic acids encoding artificial P-selectin ligands
CA2191577C (en)	2010-03-16	Method for treating and preventing atherosclerosis
AU651633B2 (en)	1994-07-28	The Mac-1 binding site of ICAM-1
WO1993005814A1 (en)	1993-04-01	Competitive inhibition of t cell-b cell interactions
EP0726942A1 (de)	1996-08-21	Menschliche schaumzellen und verfahren zu ihren herstellung, monoklonale antikörper gegen diese schaumzellen und ihre pharmazeutische und diagnostische anwendung
Tchilian	1994	Functional analysis of myeloid cell antigens
Greene	1992	Studies on the ligand binding specificity and function of the rat Kupffer cell receptor
O'Meara et al.	1994	The nephritogenic immune response